News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 03 - 06

Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio News

Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the initial dosing, marking the commencement of the Phase IV clinical stage.Efung Capital first invested in Oryzogen in 2016 and has continued to increase its commitment, participating in two consecutive fina...

浏览次数：9

查看详情>>

发布时间: 2026 - 03 - 05

Viestar’s Confocal Microscopy Products Selected as Outstanding Domestic Medical Equipment

The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the exclusive selected product in the confocal microscopy field for this batch, securing a “strong start” for the 15th Five-Year Plan with national-level authoritative certification. This achievement lays...

浏览次数：11

查看详情>>

发布时间: 2026 - 02 - 27

Monthly Health Digest | February 2026

Preface:Spring breezes blow strong as we spur our horses forward. Riding the momentum of the 2026 Spring Festival (Year of the Horse), Efung Capital received a series of good news this month: Insight Lifetech successfully listed on the Sci-Tech Innovation Board (STAR Market); three portfolio companies simultaneously advanced their Hong Kong IPOs, with all applications accepted for review.Meanwhile, more portfolio companies have achieved multi-point breakthroughs and advanced together in key sectors, writing a new chapter for China's biopharmaceutical industry with vigorous momentum.&#...

浏览次数：9

查看详情>>

发布时间: 2026 - 02 - 25

Dashi Pharmaceuticals Enters Exclusive Licensing Agreement with Slate Medicines for DS009

Dashi Pharmaceuticals (Guangdong) Co., Ltd. (“Dashi Pharmaceuticals”) today announced that it has entered into an exclusive licensing agreement with Slate Medicines, Inc., a U.S.-based biopharmaceutical company. Under the agreement, Slate Medicines will obtain the exclusive global rights (excluding Greater China) for the clinical development and commercialization of DS009 (to be named SLTE-1009 by Slate Medicines), a potentially best-in-class anti-pituitary adenylate cyclase-activating polypeptide (PACAP) monoclonal antibody independently developed by Dashan Pharmaceuticals. This antibody is i...

浏览次数：7

查看详情>>